News
Displaying 41–50 of 559
-
jCyte Launches New Phase 2 Clinical Trial for its Cell-Based RP Therapy
Research NewsThe trial is evaluating a cell dose that is 50 percent higher than the highest dose used in a previous Phase 2b trial.
-
Wet AMD Treatment Susvimo Preserves Vision for Five Years in Phase 3 Clinical Trial
Research NewsSusvimo is an FDA-approved treatment that continuously delivers drug through a tiny, implanted capsule
-
Ocugen Launches Phase 2/3 Clinical Trial for Stargardt Disease Gene-Modifier Therapy
Research NewsThe therapy delivers copies of the RORA gene to address multiple disease pathways.
-
Nanoscope Begins Rolling BLA Submission to FDA for Seeking Approval for its Optogenetic Therapy
Research NewsThe company plans to complete BLA submission in early 2026.
-
Atsena Gets FDA Nod to Expand XLRS Gene Therapy Clinical Trial to Include Pivotal Phase 3 Cohort
Research NewsThe expanded Phase 1/2/3 shortens time to potential FDA approval.
-
Advocacy Research News
In this in-depth interview hosted by InVivo, Jason Menzo, CEO of the Foundation Fighting Blindness, outlines the organization’s strategy for addressing significant changes and opportunities in the inherited retinal diseases (IRDs).
-
In the Press
Opus Genetics secures up to $2M in non-dilutive funding from the RD Fund to advance its OPGx-MERTK gene therapy program targeting retinitis pigmentosa caused by MERTK mutations.
-
José-Alain Sahel Awarded 2026 ARVO Proctor Medal for Groundbreaking Research Achievements
Research NewsDr. Sahel’s research has led to several emerging retinal disease therapies that have moved into clinical trials.
-
Advocacy Foundation News
Jason Menzo Urges Robust FY2026 Funding for National Eye Institute and Protection of Its Independent Status.
-
Advocacy Foundation News
Chairwoman Capito, Ranking Member Baldwin, and members of the Senate Appropriations Labor, Health and Human Services, Education, and Related Agencies Subcommittee, the Foundation Fighting Blindness appreciates the opportunity to provide written testimony to the subcommittee as an outside witness.
